Evidence map›Paper›PMID 36306264›Full record

ArticleCarcinogenesis2022

RAS oncogene signal strength regulates matrisomal gene expression and tumorigenicity of mouse keratinocytes.

Christophe Cataisson, Alex J Lee, Ashley M Zhang, Alicia Mizes, Serena Korkmaz, Brandi L Carofino, Thomas J Meyer, Aleksandra M Michalowski, Luowei Li, Stuart H Yuspa

Open access · hybridAbstract read
In one paragraph

Article in Carcinogenesis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Christophe CataissonLaboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA.ORCID 0000-0003-2600-1573
Alex J LeeLaboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA.ORCID 0000-0002-1825-2439
Ashley M ZhangLaboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA.
Alicia MizesLaboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA.
Serena KorkmazLaboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA.
Brandi L CarofinoLaboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA.
Thomas J MeyerCCR Collaborative Bioinformatics Resource, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Aleksandra M MichalowskiLaboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA.ORCID 0000-0001-9259-6101
Luowei LiLaboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA.
Stuart H YuspaLaboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA.ORCID 0000-0003-4785-337X
National Cancer Institute · USNational Institutes of Health · US

Funding

Interacting Signaling Pathways that Initiate Squamous Cell CarcinogenesisZIABC004504 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI YUSPA, STUART H. · 2009 to 2022
$15.7M
Intramural NIH HHS ZIA BC004504
6 · The paper itself

Abstract

Environmental and molecular carcinogenesis are linked by the discovery that chemical carcinogen induced-mutations in the Hras or Kras genes drives tumor development in mouse skin. Importantly, enhanced expression or allele amplification of the mutant Ras gene contributes to selection of initiated cells, tumor persistence, and progression. To explore the consequences of Ras oncogene signal strength, primary keratinocytes were isolated and cultured from the LSL-HrasG12D and LSL-KrasG12D C57BL/6J mouse models and the mutant allele was activated by adeno-Cre recombinase. Keratinocytes expressing one (H) or two (HH) mutant alleles of HrasG12D, one KrasG12D allele (K), or one of each (HK) were studied. All combinations of activated Ras alleles stimulated proliferation and drove transformation marker expression, but only HH and HK formed tumors. HH, HK, and K sustained long-term keratinocyte growth in vitro, while H and WT could not. RNA-Seq yielded two distinct gene expression profiles; HH, HK, and K formed one cluster while H clustered with WT. Weak MAPK activation was seen in H keratinocytes but treatment with a BRAF inhibitor enhanced MAPK signaling and facilitated tumor formation. K keratinocytes became tumorigenic when they were isolated from mice where the LSL-KrasG12D allele was backcrossed from the C57BL/6 onto the FVB/N background. All tumorigenic keratinocytes but not the non-tumorigenic precursors shared a common remodeling of matrisomal gene expression that is associated with tumor formation. Thus, RAS oncogene signal strength determines cell-autonomous changes in initiated cells that are critical for their tumor-forming potential.

Indexed as

Cell Transformation, NeoplasticGenes, rasAnimalsCarcinogenesisGene ExpressionKeratinocytesMiceMice, Inbred C57BL

Identifiers

PMID36306264
PMCPMC10122430
OpenAlexW4307497968

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.